Seqirus news releases
Seqirus starts on time delivery of flu vaccines to support NHS immunisation programmes across the UK
This news release is intended for Health Professional media only.
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
Seqirus, a global leader in influenza prevention, today presented new scientific data at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore that demonstrated circulating influenza B/Victoria (B/Vic) viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.
Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response
Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines at OPTIONS X Conference
Seqirus announced it will feature data in 3 presentations and 24 posters on the company’s adjuvant and cell-based vaccines for seasonal and pandemic influenza at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.
Seqirus opens new Italian headquarters
Seqirus, a global leader in influenza prevention, today opened its new Italian headquarters in San Martino, Monteriggioni, just outside Siena.
Anjana Narain to Lead Seqirus Influenza Vaccines Business
CSL Limited today named Anjana Narain, a seasoned leader in vaccines and biopharmaceuticals, as Executive Vice President and General Manager of its Seqirus business, one of the world’s largest influenza vaccines providers.